Low prevalence of JAK2 V617F mutation in patients with thrombosis and normal blood counts: a retrospective impact study
- 7 April 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Journal of Thrombosis and Thrombolysis
- Vol. 50 (4), 995-1003
- https://doi.org/10.1007/s11239-020-02100-z
Abstract
To determine the prevalence of the V617F Janus Kinase 2 (JAK2) mutation in patients with thrombosis without other biological signs of underlying myeloproliferative neoplasm (MPN) and identify associated risk factors for thrombosis. Over a 10-year period, data were collected from patients with thrombotic events and who had also been screened for the V617F JAK2 mutation. Patients with signs of underlying MPN, such as haematocrit levels ≥ 50% and/or platelet counts ≥ 450 × 109/L and/or splanchnic thrombosis were excluded from the study. Of 340 patients fulfilling inclusion criteria, JAK2 mutation was found in 9 (2.65%), the allele burden being at least 2% in 4 (1.1%). Upon follow-up, MPN was diagnosed in the latter 4. Univariate analysis of the whole cohort showed that age (54 ± 15 vs. 64 ± 13, p = 0.027), platelet count (317 ± 111 vs. 255 ± 75, p = 0.017), C-reactive protein level > 5 mg/L (OR 7.29, p = 0.014), and splenomegaly (OR 54.5, p = 0.0002) were significantly associated with JAK2 mutation. There was also a trend for an increased risk of cerebral venous thrombosis (OR 6.54, p = 0.064). Logistic regression confirmed a significant association between splenomegaly and JAK2 mutation (OR 43.15 [95%CI, 3.05–610.95], p = 0.0054). The V617F JAK2 mutation is rarely found in patients with thrombotic events without overt MPN. Splenomegaly, however, is a statistically and clinically relevant indicator of a potential JAK2 mutation in patients with non-splanchnic thrombotic events. Such patients should require further assessment and a close follow-up.Keywords
This publication has 40 references indexed in Scilit:
- Spleen endothelial cells from patients with myelofibrosis harbor the JAK2V617F mutationBlood, 2013
- Development and validation of an International Prognostic Score of thrombosis in World Health Organization–essential thrombocythemia (IPSET-thrombosis)Blood, 2012
- The JAK2 V617F mutation in patients with cerebral venous thrombosisJournal of Thrombosis and Haemostasis, 2012
- Endothelial progenitor cells are clonal and exhibit the JAK2V617F mutation in a subset of thrombotic patients with Ph-negative myeloproliferative neoplasmsBlood, 2011
- The JAK2 V617F somatic mutation, mortality and cancer risk in the general populationHaematologica, 2010
- JAK2V617F mutation in patients with thrombosis: to screen or not to screen?International Journal of Laboratory Hematology, 2010
- JAK2V617F Mutation in Patients with Splanchnic Vein ThrombosisDigestive Diseases and Sciences, 2009
- Perspectives on thrombosis in essential thrombocythemia and polycythemia vera: is leukocytosis a causative factor?Blood, 2009
- The presence of JAK2V617F mutation in the liver endothelial cells of patients with Budd-Chiari syndromeBlood, 2009
- Incidence of the JAK2 V617F mutation among patients with splanchnic or cerebral venous thrombosis and without overt chronic myeloproliferative disordersJournal of Thrombosis and Haemostasis, 2007